US 12,419,914 B2
Thrombosomes as an antiplatelet agent reversal agent
Keith Andrew Moskowitz, Westfield, IN (US); Braden Carl Ishler, Montgomery Village, MD (US); William Matthew Dickerson, Washington, DC (US); Narendra Nath Tandon, Gaithersburg, MD (US); Amber Nicole Lee, Montgomery Village, MD (US); and Glen Michael Fitzpatrick, North Potomac, MD (US)
Assigned to Cellphire, Inc., Rockville, MD (US)
Filed by Cellphire, Inc., Rockville, MD (US)
Filed on May 16, 2023, as Appl. No. 18/318,548.
Application 18/318,548 is a continuation of application No. 16/994,377, filed on Aug. 14, 2020, granted, now 11,701,388.
Claims priority of provisional application 63/065,337, filed on Aug. 13, 2020.
Claims priority of provisional application 62/887,923, filed on Aug. 16, 2019.
Prior Publication US 2023/0285465 A1, Sep. 14, 2023
Int. Cl. A61K 35/19 (2015.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61K 47/42 (2017.01); A61P 7/04 (2006.01)
CPC A61K 35/19 (2013.01) [A61K 45/06 (2013.01); A61K 47/26 (2013.01); A61K 47/42 (2013.01); A61P 7/04 (2018.01)] 20 Claims
 
1. A method of treating bleeding in a human subject, the method comprising
administering to the human subject in need thereof, an effective amount of a rehydrated composition comprising freeze-dried platelet derivatives (FDPDs) and an incubating agent comprising one or more saccharides, one or more salts, and a buffer,
wherein the one or more saccharides comprise trehalose in the range of 10 mM to 500 mM,
wherein the FDPDs have less than 10% crosslinking of platelet membranes via proteins and/or lipids present on the membranes, and 50% to 99% of the FDPDs have a diameter in the range of 0.3 μm to 5.0 μm,
wherein the human subject is being treated with aspirin and an antiplatelet agent selected from the group consisting of cangrelor, ticagrelor, prasugrel, abciximab, terutroban, picotamide, elinogrel, vorapaxar, atopaxar, cilostazol, epoprostenol, dipyridamole, treprostinil sodium, sarpogrelate, clopidogrel, eptifibatide, tirofiban, and ticlopidine, such that treatment with aspirin and the antiplatelet agent is continued before and after the administering without stopping the treatment,
wherein the administering comprises administering parenterally or topically, and
wherein the effective amount of the composition is at least 5.0×109 FDPDs/kg of the human subject.